|Application ||WB, IHC-P, E|
|Calculated MW||53154 Da|
|Antigen Region||37-65 aa|
|Other Names||Angiotensinogen, Serpin A8, Angiotensin-1, Angiotensin 1-10, Angiotensin I, Ang I, Angiotensin-2, Angiotensin 1-8, Angiotensin II, Ang II, Angiotensin-3, Angiotensin 2-8, Angiotensin III, Ang III, Des-Asp-angiotensin II, Angiotensin-4, Angiotensin 3-8, Angiotensin IV, Ang IV, Angiotensin 1-9, Angiotensin 1-7, Angiotensin 1-5, Angiotensin 1-4, AGT, SERPINA8|
|Target/Specificity||This AGT antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 37-65 amino acids from the N-terminal region of human AGT.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Precautions||AGT Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Essential component of the renin-angiotensin system (RAS), a potent regulator of blood pressure, body fluid and electrolyte homeostasis. Angiotensin-3: stimulates aldosterone release.|
|Tissue Location||Expressed by the liver and secreted in plasma.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
AGT, pre-angiotensinogen or angiotensinogen precursor, is expressed in the liver and is cleaved by the enzyme renin in response to lowered blood pressure. The resulting product, angiotensin I, is then cleaved by angiotensin converting enzyme (ACE) to generate the physiologically active enzyme angiotensin II. The protein is involved in maintaining blood pressure and in the pathogenesis of essential hypertension and preeclampsia. Mutations in AGT gene are associated with susceptibility to essential hypertension, and can cause renal tubular dysgenesis, a severe disorder of renal tubular development. Defects in AGT gene have also been associated with non-familial structural atrial fibrillation, and inflammatory bowel disease.
Gurkan,A., Arch. Oral Biol. 54 (4), 337-344 (2009)
Vickers,C., J. Biol. Chem. 277 (17), 14838-14843 (2002)
Donoghue,M., Circ. Res. 87 (5), E1-E9 (2000)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.